Delcath Systems, Inc. (DCTH) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals: a slight revenue increase, improved gross margins, and significant R&D investments, but decreased net income and higher expenses. The guidance reflects slower site activations and a modest revenue outlook. The Q&A highlighted uncertainties in trial timelines and utilization impacts. Despite strong gross margins and promising trials, the inability to overshoot site guidance and potential revenue step-downs suggest limited short-term stock movement, leading to a neutral sentiment.
Key Financial Performance
Revenue from HEPZATO $19.3 million for Q3 2025, compared to $10 million for the same period in 2024, representing a significant year-over-year increase. The increase is attributed to higher sales volume.
Revenue from CHEMOSAT $1.3 million for Q3 2025, compared to $1.2 million for the same period in 2024, showing a slight year-over-year increase.
Gross Margins 87% in Q3 2025, compared to 85% in Q3 2024, reflecting a 2% improvement year-over-year. This improvement is due to operational efficiencies.
Research and Development Expenses $8.0 million for Q3 2025, compared to $3.9 million for the same period in 2024, representing a significant increase. The rise is due to increased investment in clinical trials and development activities.
Selling, General and Administrative Expenses $10.3 million for Q3 2025, compared to $7.0 million for the same period in 2024, showing a substantial increase. This is attributed to the expansion of the sales force and administrative costs.
Net Income $0.8 million for Q3 2025, compared to $1.9 million for the same period in 2024, reflecting a decrease. The decline is due to higher operating expenses.
Non-GAAP Adjusted EBITDA $5.3 million for Q3 2025, compared to $1.0 million for the same period in 2024, showing a significant improvement. This is due to increased revenue and operational efficiencies.
Cash and Investments $89 million at the end of Q3 2025, with quarterly positive operating cash flow of $4.8 million, compared to $7.3 million in Q2 2025. The decrease in cash flow is due to higher R&D and SG&A expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
HEPZATO and CHEMOSAT Revenue: Revenue from HEPZATO was $19.3 million and CHEMOSAT was $1.3 million for Q3 2025, compared to $10 million for HEPZATO and $1.2 million for CHEMOSAT in Q3 2024.
CHOPIN Trial Results: The CHOPIN trial showed a 1-year PFS of 54.7% in the combination group versus 15.8% in the perfusion group, with improved median overall survival (23.1 months vs. 19.6 months) and best overall response rate (76.3% vs. 39.5%). Results were statistically significant.
New Trials: Two company-sponsored trials are ongoing for liver-dominant metastatic colorectal cancer and breast cancer, with interim data expected in 2027 and primary endpoint results in 2028-2029.
Site Expansion: Activated 4 new sites in the past 2 months, with 25 REMS-certified treatment sites currently. Plans to reach 26-28 active sites by end of 2025 and 40 by end of 2026.
Sales Force Expansion: U.S. sales force expanded from 4 to 6 regions in 2025, with plans to grow to 9 regions by Q2 2026.
Gross Margins: Gross margins were 87% in Q3 2025, compared to 85% in Q3 2024. Forecast for 2025 gross margins is 85%-87%.
Cash Flow: Quarterly positive operating cash flow was $4.8 million in Q3 2025, compared to $7.3 million in Q2 2025.
Future Indications for HEPZATO: Plans to develop HEPZATO for intrahepatic cholangiocarcinoma, cutaneous metastatic melanoma, and non-small cell lung cancer in combination with checkpoint inhibitors. Development plans to be finalized in 3-6 months.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Impact: The 340B pricing related to NDRA participation caused a 13% reduction in average revenue per kit sold in Q3 2025, with similar pricing expected in Q4.
Site Activation Challenges: A slowdown in the pace of site activation occurred from June to August, though it has since returned to a steadier pace. However, challenges in activating and maintaining active treatment sites remain.
Seasonality and Scheduling Constraints: Seasonal factors, such as summer and holiday periods, led to a slowdown in new patient starts due to scheduling capacity challenges for HEPZATO treatments.
Competitive Pressures: Increased competition from other clinical trials, such as Replimune-sponsored trials and Thomas Jefferson's single-center trials, impacted patient recruitment and trial participation.
Physician Reluctance: Some physicians are hesitant to use HEPZATO for patients with extrahepatic disease, despite evidence supporting its efficacy. This reluctance may limit adoption.
Operational Costs: Research and development expenses increased significantly to $8.0 million in Q3 2025 from $3.9 million in the prior year, and selling, general, and administrative expenses also rose to $10.3 million from $7.0 million.
Future Trial Uncertainties: The company is conducting trials for metastatic CRC and breast cancer, with results expected between 2027 and 2030. Delays or challenges in these trials could impact future growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company adjusted its 2025 annual revenue guidance to $83 million to $85 million.
Site Activation and Expansion: The company plans to have 26 to 28 active treating centers by the end of 2025 and 40 centers by the end of 2026. Expansion of the U.S. sales force from 6 to 9 regions is planned by the second quarter of 2026 to support site activation and referral network building.
Clinical Trials and Data Release: Interim data for the metastatic CRC trial is expected in the second quarter of 2027, with primary endpoint results in mid-2028 and overall survival data in 2029. For the metastatic breast cancer trial, interim data is expected in the fourth quarter of 2027, with primary endpoint results in mid-2029 and overall survival data in 2030.
Future Development Plans: Development plans for new combination trials in other indications, such as intrahepatic cholangiocarcinoma, cutaneous metastatic melanoma, and non-small cell lung cancer, are expected to be finalized within 3 to 6 months.
Gross Margins and Financial Projections: Gross margins for 2025 are forecasted to be between 85% and 87%, with continued positive non-GAAP adjusted EBITDA and positive cash flow for the rest of the year.
HEPZATO Treatment Volume: The total HEPZATO treatment volume in 2025 is projected to increase by nearly 150% compared to 2024.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is built into Q4 expectations regarding competitive clinical trial activity and seasonality?
A:The guidance assumes a modest amount of seasonality in Q4, though the company has limited historical data. They were surprised by summer seasonality and factored in similar levels of clinical trial competition as seen midyear.
Q:How do you expect site additions to roll out into 2026?
A:Site additions are expected to accelerate in the back half of the year, with a potential 40-60 split in terms of timing.
Q:What steps are being taken to improve utilization in lower volume accounts?
A:The company is building referral networks to sites with fewer patients, expanding the sales force and medical affairs team, and working to change physician prescribing behavior. Disseminating CHOPIN data is also seen as important.
Q:When is CHOPIN expected to impact utilization?
A:CHOPIN is expected to start impacting utilization in 2026, with a meaningful publication potentially coming in December. The impact will grow as 2026 progresses.
Q:How are investigators addressing neutropenia in the Phase II HEPZATO combo trial?
A:Investigators are managing neutropenia through standard supportive care, dosing adjustments, drug holidays, and G-CSF usage, as defined in the protocol.
Q:How should we think about the NDRA program's influence on profitability and revenue growth?
A:The NDRA program is expected to cause a one-time step down in revenue. The average revenue per kit is not anticipated to change dramatically. Participation rates and discounts are expected to remain consistent. Gross margins are projected to be 80-85% into 2026, with potential for high 80% beyond 2026.
Q:What is the likelihood of overshooting the guidance of 28 active centers by year-end?
A:It is highly unlikely to overshoot the guidance. While there are 7 centers on deck, only 1 to 3 are expected to come online by year-end.
Q:What is the status of the European investigator-sponsored SCANDIUM-3 trial?
A:The SCANDIUM-3 trial is recruiting slowly, and there is no timeline for data readout. It is considered too distant for projection purposes.
Q:How is capital being allocated between top-line growth and increased R&D expenses?
A:Capital allocation is determined on a program-by-program basis. The company has a fixed R&D budget for ongoing trials and IITs. Decisions are based on the merits of each program, with sufficient capital available to fund projects from the top line or other means if compelling.
Q:How much read-through is there from CHOPIN's success to new combinations in breast and colorectal cancer?
A:CHOPIN's success validates systemic treatment with HEPZATO. The company is exploring the potential for adding checkpoint inhibitors to treatment paradigms in colorectal and breast cancer, particularly in areas where IOs are established.
Q:Can you quantify the impact of Thomas Jefferson's single-center trials on patient enrollment?
A:Thomas Jefferson has 109 patients in their single-center trials, which is the highest among centers conducting such trials.
Q:Review of Unclear Management Responses
A:Management avoided providing a timeline for the SCANDIUM-3 trial's data readout, citing slow recruitment and the distant future as reasons. Additionally, they could not quantify the impact of the NDRA program on volume growth, stating it was 'impossible to know' without a parallel universe for comparison.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CHOPIN protocol
CHOPIN trial
Canaccord Genuity
Co LLC
Corp Research
Division Canaccord
Division HC
Dr
General Corporate
Genuity Corp
HEPZATO patient
LLC Research
Professor
REMS
Research Division
call
collaboration
combination therapy
disease
expansion site
induction
maintenance therapy
opinion leader
outcome
pace site
patient mets
patient start
physician therapy
practice
protocol therapy
release
response rate
result CHOPIN
seasonality
site activation
summer
therapy patient
trial CHOPIN
DCTH Transcript
Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call indicates strong financial performance with a 25% revenue increase and improved gross margin. Although there is a net loss, it has decreased from the previous year, signaling better cost management. The company's guidance for 2026 shows optimism with expected revenue growth and strategic expansions. Despite some risks and uncertainties, the overall financial health and strategic outlook suggest a positive sentiment, likely resulting in a stock price increase over the next two weeks.
Delcath Systems, Inc. (DCTH) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call highlights strong financial metrics, including high projected gross margins and revenue growth. Despite some concerns about cash flow and unclear guidance on CHOPIN's impact, the company's strategic expansion plans and focus on long-term value are promising. The Q&A section reveals a cautious but optimistic outlook, with potential catalysts like new center activations and the CHOPIN study publication. Overall, the positive financial projections and strategic growth initiatives suggest a likely positive stock price movement in the short term.
Wajax Corporation (WJX:CA) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call presents a mixed picture. Equipment and product support sales slightly decreased, while ERS sales increased. The backlog and inventory decreased, but cash flows improved significantly. The Q&A reveals resilience in mining and energy, but caution in automotive and forestry. The company is comfortable with cost optimization and prepared for future demand. However, uncertainties in market dynamics and vague management responses on policy impacts create a neutral sentiment. The lack of a market cap and mixed financial performance suggest a neutral stock price movement within -2% to 2%.
Delcath Systems, Inc. (DCTH) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call presents mixed signals: a slight revenue increase, improved gross margins, and significant R&D investments, but decreased net income and higher expenses. The guidance reflects slower site activations and a modest revenue outlook. The Q&A highlighted uncertainties in trial timelines and utilization impacts. Despite strong gross margins and promising trials, the inability to overshoot site guidance and potential revenue step-downs suggest limited short-term stock movement, leading to a neutral sentiment.
DCTH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
